140 related articles for article (PubMed ID: 23489175)
1. Safety assessment of subconjunctivally implanted devices containing latanoprost in Dutch-belted rabbits.
Jessen BA; Shiue MH; Kaur H; Miller P; Leedle R; Guo H; Evans M
J Ocul Pharmacol Ther; 2013; 29(6):574-85. PubMed ID: 23489175
[TBL] [Abstract][Full Text] [Related]
2. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma.
Kashiwagi K; Ito K; Haniuda H; Ohtsubo S; Takeoka S
Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5629-37. PubMed ID: 23868986
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable nanoparticles for controlled subconjunctival delivery of latanoprost acid: in vitro and in vivo evaluation. Preliminary results.
Giarmoukakis A; Labiris G; Sideroudi H; Tsimali Z; Koutsospyrou N; Avgoustakis K; Kozobolis V
Exp Eye Res; 2013 Jul; 112():29-36. PubMed ID: 23603320
[TBL] [Abstract][Full Text] [Related]
4. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
7. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
8. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
9. The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts.
Lark KK; Pasha AS; Yan X; Edward DP
J Glaucoma; 1999 Feb; 8(1):72-6. PubMed ID: 10084277
[TBL] [Abstract][Full Text] [Related]
10. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.
Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS
Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828
[TBL] [Abstract][Full Text] [Related]
12. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
13. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma.
Sato S; Hirooka K; Baba T; Mizote M; Fujimura T; Tenkumo K; Ueda H; Shiraga F
J Ocul Pharmacol Ther; 2011 Oct; 27(5):499-502. PubMed ID: 21790301
[TBL] [Abstract][Full Text] [Related]
15. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients.
Costagliola C; Del Prete A; Verolino M; Antinozzi P; Fusco R; Parmeggiani F; Mastropasqua L
Graefes Arch Clin Exp Ophthalmol; 2002 May; 240(5):379-86. PubMed ID: 12073061
[TBL] [Abstract][Full Text] [Related]
16. Intraocular pressure control among patients transitioned from latanoprost to travoprost at a Veterans Affairs Medical Center Eye Clinic.
McKinley SH; Singh R; Chang PT; Gross RL; Orengo-Nania S
J Ocul Pharmacol Ther; 2009 Apr; 25(2):153-7. PubMed ID: 19284329
[TBL] [Abstract][Full Text] [Related]
17. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
18. Effects of 0.005% latanoprost solution on intraocular pressure in healthy dogs and cats.
Studer ME; Martin CL; Stiles J
Am J Vet Res; 2000 Oct; 61(10):1220-4. PubMed ID: 11039551
[TBL] [Abstract][Full Text] [Related]
19. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
Sutton A; Gilvarry A; Ropo A
J Ocul Pharmacol Ther; 2007 Aug; 23(4):359-65. PubMed ID: 17803434
[TBL] [Abstract][Full Text] [Related]
20. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Schachar RA; Raber S; Courtney R; Zhang M
Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
